MedImmune, LLC
MedImmune LLC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
38
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name MedImmune, LLC as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:57 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03889275 · A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid TumorsMedImmune LLC · completed · Advanced Solid Tumors
- Ph1NCT03489525 · MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaMedImmune LLC · completed · Relapsed/Refractory Multiple Myeloma
- Ph1/Ph2NCT03381274 · Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyMedImmune LLC · active not recruiting · Carcinoma, Non-Small-Cell Lung
- Ph1/Ph2NCT03162224 · Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerMedImmune LLC · completed · Head and Neck Cancer, Human Papilloma Virus
- Ph1NCT03089645 · MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.MedImmune LLC · completed · Advanced Solid Tumors
- Ph1NCT02991911 · A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate CancerMedImmune LLC · completed · Metastatic Castration Resistant Prostate Cancer
- Ph1NCT02900157 · Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid TumorsMedImmune LLC · completed · Advanced Solid Tumors
- Ph2NCT02696902 · Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated SubjectsMedImmune LLC · completed · Pseudomonas Aeruginosa
- Ph1NCT02583165 · A Study in Adult Subjects With Select Advanced Solid TumorsMedImmune LLC · completed · Advanced Solid Tumors
- Ph1NCT02576548 · A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.MedImmune LLC · completed · HER2 Expressing Breast or Gastric/Stomach Cancers
- Ph1NCT02556463 · A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid TumorsMedImmune LLC · terminated · Solid Tumors, CTCL, Cancer
- Ph1NCT02549651 · MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)MedImmune LLC · completed · Diffuse Large B-Cell Lymphoma
- Ph2NCT02519348 · A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaMedImmune LLC · active not recruiting · Hepatocellular Carcinoma · study director
- Ph1NCT02503774 · MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.MedImmune LLC · completed · Solid Tumors
- Ph1/Ph2NCT02340975 · A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ AdenocarcinomaMedImmune LLC · completed · Gastric or Gastroesophageal Junction Adenocarcinoma · study director
- Ph1NCT02318394 · A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid TumorsMedImmune LLC · completed · Advanced Solid Tumors
- Ph2NCT02296320 · Study of the Efficacy and Safety of MEDI4893MedImmune LLC · completed · Staphylococcus Aureus Pneumonia
- Ph1/Ph2NCT02271945 · Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell LymphomasMedImmune LLC · completed · Relapsed/Refractory Aggressive B-cell Lymphomas
- Ph1NCT02262741 · A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerMedImmune LLC · completed · Squamous Cell Carcinoma of the Head and Neck
- Ph1NCT02261220 · A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid TumorsMedImmune LLC · completed · Advanced Solid Tumors
- Ph1/Ph2NCT02205333 · A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesMedImmune LLC · terminated · Advanced Solid Tumors, Aggressive B-cell Lymphomas · study director
- Ph2/Ph3NCT02200770 · N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersMedImmune LLC · completed · Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders · study director
- Ph1NCT02117219 · Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic SyndromeMedImmune LLC · completed · Myelodysplastic Syndrome
- Ph2
- Ph1NCT02027961 · Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib AloneMedImmune LLC · completed · Melanoma
- Ph1NCT02000947 · A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung CancerMedImmune LLC · completed · NSCLC, Non-small Cell Lung Cancer, Lung Cancer
- Ph3NCT01829711 · Moxetumomab Pasudotox for Advanced Hairy Cell LeukemiaMedImmune LLC · completed · Leukemia, Hairy Cell
- Ph1/Ph2NCT01693562 · A Phase 1/2 Study to Evaluate MEDI4736MedImmune LLC · completed · Advanced Solid Tumors · unknown
- Ph2NCT01453205 · A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)MedImmune LLC · completed · Diffuse Large B-Cell Lymphoma
- Ph2NCT01446159 · Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast CancerMedImmune LLC · completed · Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
- Ph1/Ph2NCT01268059 · A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung CancerMedImmune LLC · terminated · Non-small Cell Lung Cancer
- Ph1NCT01248949 · A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid TumorsMedImmune LLC · completed · Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors · study director
- Ph1NCT00974675 · A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate AsthmaMedImmune LLC · terminated · Moderate Asthma
- Ph2NCT00873860 · Study to Evaluate the Safety and Efficacy of CAT-354MedImmune LLC · completed · Asthma
- Ph1NCT00659425 · CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaMedImmune LLC · completed · Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- Ph1NCT00638989 · A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354MedImmune LLC · completed · Asthma, Healthy
- Ph1NCT00586924 · A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell LeukemiaMedImmune LLC · completed · Hairy Cell Leukemia
- Ph3NCT00121108 · MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United StatesMedImmune LLC · completed · Healthy · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.